Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2003 2
2004 1
2005 2
2006 1
2007 7
2008 3
2009 4
2010 3
2011 3
2012 10
2013 4
2014 2
2015 2
2016 2
2017 4
2018 5
2019 4
2020 1
2021 2
2022 1
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.
Aschoff R, Möller S, Haase R, Kuske M. Aschoff R, et al. J Drugs Dermatol. 2021 Mar 1;20(3):295-301. doi: 10.36849/JDD.2021.5641. J Drugs Dermatol. 2021. PMID: 33683070 Clinical Trial.
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tretinoin 0.025% (CT) and benzoyl peroxide 2.5%-adapalene 0.1% (BA) in 20 patients with mild to moderate acne vulgaris. ...
This evaluator-blinded pilot study compared the efficacy and tolerability of two marketed topical combination acne gels, clindamycin 1%-tret …
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Stein Gold L, et al. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. Am J Clin Dermatol. 2022. PMID: 34674160 Free PMC article. Clinical Trial.
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne. METHODS: In a phase II, double-blind, multicente …
OBJECTIVES: We aimed to evaluate the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.
Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Kerrouche N, Tan J. Dréno B, et al. Am J Clin Dermatol. 2018 Apr;19(2):275-286. doi: 10.1007/s40257-018-0352-y. Am J Clin Dermatol. 2018. PMID: 29549588 Free PMC article. Clinical Trial.
BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patien …
BACKGROUND: Very few clinical trials have investigated the effect of topical acne treatment on scarring. OBJECTIVES: Our objective was to ev …
Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.
Draelos ZD, Baalbaki N, Colon G, Dreno B. Draelos ZD, et al. J Drugs Dermatol. 2023 Jun 1;22(6):554-558. doi: 10.36849/JDD.7142. J Drugs Dermatol. 2023. PMID: 37276158 Clinical Trial.
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicular keratinization and BPO to decrease the C. acnes population. .. …
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl
Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials.
Draelos ZD, Tanghetti EA, Kircik LH, Bhatia N, Zeichner JA, Sugarman JL, Stein Gold L. Draelos ZD, et al. J Dermatolog Treat. 2023 Dec;34(1):2220446. doi: 10.1080/09546634.2023.2220446. J Dermatolog Treat. 2023. PMID: 37341243 Free article. Clinical Trial.
Herein are the dermal sensitization, irritation, safety, and tolerability results from phase 1 and 2 studies of fixed-dose clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) polymeric mesh gel. ...IDP-126 (deemed "moderately irri …
Herein are the dermal sensitization, irritation, safety, and tolerability results from phase 1 and 2 studies of fixed-dose clindamycin phosp …
Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24 weeks and assessment of atrophic acne scars using three-dimensional image analysis.
Tanizaki H, Hayashi N, Abe M. Tanizaki H, et al. J Dermatol. 2023 Dec;50(12):1513-1522. doi: 10.1111/1346-8138.16942. Epub 2023 Sep 4. J Dermatol. 2023. PMID: 37665181 Clinical Trial.
Compared with the control group, the success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups (P = 0.0006 for both). ...Adverse drug reactions were noted in three patients in the adapalene/b
Compared with the control group, the success rates were significantly higher in the adapalene/benzoyl peroxide and b
Early and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel.
Harper JC, Kircik LH, Gold M, Hebert AA, Sugarman JL, Green L, Gold LS, Baldwin H, Guenin E, DelRosso JQ. Harper JC, et al. J Drugs Dermatol. 2024 Mar 1;23(3):125-131. doi: 10.36849/jdd.7907. J Drugs Dermatol. 2024. PMID: 38443130 Clinical Trial.
This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel—the first FDA-approved triple-combination topical acne product—to its dyads and vehicle. ...
This post hoc analysis compared threshold acne lesion reductions with clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl pe
Adapalene/Benzoyl Peroxide Gel 0.3%/2.5%: A Safe and Effective Acne Therapy in All Skin Phototypes.
Alexis AF, Cook-Bolden FE, York JP. Alexis AF, et al. J Drugs Dermatol. 2017 Jun 1;16(6):574-581. J Drugs Dermatol. 2017. PMID: 28686775 Clinical Trial.
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% benzoyl peroxide (A/BPO gel 0.3%/2.5%) in subjects with Fitzpatrick Skin Types (FST) I-VI....
This analysis investigated possible differences in the efficacy and safety of the fixed dose combination of 0.3% adapalene with 2.5% …
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
Eichenfield LF, Stein Gold L, Kircik LH, Werschler WP, Beer K, Draelos ZD, Tanghetti EA, Papp KA, Baldwin H, Lain E, Sadick N, Gooderham MJ, Konda A. Eichenfield LF, et al. Pediatr Dermatol. 2023 May-Jun;40(3):452-459. doi: 10.1111/pde.15283. Epub 2023 Mar 22. Pediatr Dermatol. 2023. PMID: 36949579 Clinical Trial.
BACKGROUND/OBJECTIVES: Topical clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) is the first fixed-dose triple-combination formulation in development for acne. ...
BACKGROUND/OBJECTIVES: Topical clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel (IDP-126) is the fi …
Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris.
Korkut C, Piskin S. Korkut C, et al. J Dermatol. 2005 Mar;32(3):169-73. doi: 10.1111/j.1346-8138.2005.tb00739.x. J Dermatol. 2005. PMID: 15863861 Clinical Trial.
Benzoyl peroxide and adapalene are among the most effective topical agents used in the treatment of acne. ...The patients were randomly divided into three groups with 35 patients in each. The groups were randomly assigned to 0.1% adapalene gel, 5% b
Benzoyl peroxide and adapalene are among the most effective topical agents used in the treatment of acne. ...The patien
70 results